id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268140-s5lailkp	Atal, Shubham	IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?	2020-06-13		.txt	text/plain	5174	258	41	Considering the proven role of cytokine dysregulation in causing this hyperinflammation in the lungs with IL-6 being a key driver, particularly in seriously ill COVID-19 patients, it is crucial to further explore selective cytokine blockade with drugs like the IL-6 inhibitors tocilizumab, sarilumab, and siltuximab. Considering the proven role of cytokine dysregulation in serious COVID-19 and interleukin (IL)-6 being the key driver of this hyperinflammation, which can cause multi-organ failure, a series of clinical trials with IL-6 inhibitors like tocilizumab, sarilumab and siltuximab are underway. Another Italian Phase II open-label trial (NCT04315480) with tocilizumab 8 mg/kg single dose is being conducted in patients with severe multifocal interstitial pneumonia due to COVID-19 to evaluate its role in the virus-induced cytokine storm, in blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing naso-tracheal intubation and/or death [51] .	./cache/cord-268140-s5lailkp.txt	./txt/cord-268140-s5lailkp.txt